Boehringer Ingelheim confirms annual sales guidance as first-half revenue rises, led by Jardiance

Headline results for the first half:

Prescription drug sales

€6.8 billion ($7.5 billion)

Versus €6.1 billion ($6.7 billion)

Revenue

€9.3 billion ($10.3 billion)

+4.6%

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

"We are pleased with our half-year result. Boehringer Ingelheim is growing organically in a sustainable and stable manner," remarked Hubertus von Baumbach, chairman of the board of managing directors. The company noted that "business conditions remained good across all regions," adding that in Japan, the drugmaker "is now once again expanding following a decline in revenues in recent years."

Other results:

  • Jardiance: €1 billion ($1.1 billion), +44.8%
  • Ofev: €677 million ($747 million), +21.6%
  • Biopharmaceutical contract manufacturing: €273 million ($301 million), down from €298 million ($329 million) in the prior year, with results adversely impacted by unfavourable phase effects

Looking ahead:

Boehringer Ingelheim reaffirmed that it expects "slight" growth in net sales this year.

To read more Top Story articles, click here.